Accuray (NASDAQ:ARAY) Cut to “Hold” at StockNews.com

StockNews.com cut shares of Accuray (NASDAQ:ARAY) from a buy rating to a hold rating in a report released on Tuesday morning.

Accuray Stock Down 4.0 %

Shares of NASDAQ ARAY opened at $2.16 on Tuesday. Accuray has a 52 week low of $1.40 and a 52 week high of $2.95. The stock’s fifty day moving average is $2.15 and its 200 day moving average is $2.00. The company has a debt-to-equity ratio of 3.51, a quick ratio of 0.88 and a current ratio of 1.62. The stock has a market capitalization of $222.11 million, a P/E ratio of -43.20 and a beta of 1.51.

Accuray (NASDAQ:ARAY) last issued its earnings results on Wednesday, February 5th. The medical equipment provider reported $0.02 EPS for the quarter, beating the consensus estimate of ($0.01) by $0.03. Accuray had a negative net margin of 0.96% and a negative return on equity of 9.75%. Sell-side analysts forecast that Accuray will post 0.01 earnings per share for the current fiscal year.

Institutional Trading of Accuray

Several large investors have recently bought and sold shares of ARAY. Heartland Advisors Inc. boosted its stake in shares of Accuray by 14.1% in the 4th quarter. Heartland Advisors Inc. now owns 3,824,750 shares of the medical equipment provider’s stock valued at $7,573,000 after purchasing an additional 472,800 shares in the last quarter. Renaissance Technologies LLC grew its position in Accuray by 6.8% during the 4th quarter. Renaissance Technologies LLC now owns 2,979,998 shares of the medical equipment provider’s stock worth $5,900,000 after acquiring an additional 189,414 shares during the last quarter. Foundry Partners LLC raised its position in Accuray by 51.3% in the third quarter. Foundry Partners LLC now owns 2,187,160 shares of the medical equipment provider’s stock valued at $3,937,000 after purchasing an additional 741,900 shares during the last quarter. Geode Capital Management LLC boosted its stake in shares of Accuray by 0.3% during the fourth quarter. Geode Capital Management LLC now owns 2,186,154 shares of the medical equipment provider’s stock valued at $4,329,000 after purchasing an additional 6,758 shares in the last quarter. Finally, State Street Corp increased its stake in shares of Accuray by 3.8% in the third quarter. State Street Corp now owns 1,894,287 shares of the medical equipment provider’s stock valued at $3,410,000 after buying an additional 70,008 shares during the period. 64.08% of the stock is owned by institutional investors and hedge funds.

Accuray Company Profile

Accuray Incorporated designs, develops, manufactures, and sells radiosurgery and radiation therapy systems for the treatment of tumors in the United States, Canada, Latin America, Asia, Australia, New Zealand, Europe, the Middle East, India, Africa, Japan, and China. It offers the CyberKnife platform, a robotic stereotactic radiosurgery and stereotactic body radiation therapy system used for the treatment of primary and metastatic tumors outside the brain, including tumors on or near the spine and in the breast, kidney, liver, lung, pancreas, and prostate.